Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lepodisiran in adults with elevated Lp(a) and cardiovascular disease
NCT07613294Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2026
- Primary completion
- Dec 2029
- Countries
- 7
01
Overview
A Phase 3 trial of lepodisiran in atherosclerotic cardiovascular disease (ASCVD), sponsored by Eli Lilly and Company. Started Jun 2026; status: recruiting.
02
Drugs
lepodisiran
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT07613294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07613294.